Palo Alto, Calif. — November 4, 2025 — Leads & Copy — Scilex Holding Company (Nasdaq: SCLX) has secured a worldwide exclusive license to Datavault AI’s technology for the biotech and biopharma industry, enabling a Biotech Exchange platform. The platform will allow Scilex to utilize secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data. The company believes it can tokenize about $2.0 trillion in pharmaceutical and diagnostic drug sales, and that tokenization could offer an alternative way for companies to raise non-dilutive funding.
The license includes Datavault AI’s intellectual property, notably the pending patent for “Platform and Method for Tokenizing DNA Data”. Scilex will pay a non-refundable upfront license fee in four equal installments of $2.5 million each on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Datavault will earn sales milestone payments of up to an aggregate of $2.55 billion upon the achievement of certain applicable sales milestones.
For investor and media inquiries, contact Scilex Holding Company at 960 San Antonio Road, Palo Alto, CA 94303, call (650) 516-4310, or email investorrelations@scilexholding.com.
Source: Scilex Holding Company
